Literature DB >> 11472104

A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells.

H Stecher1, D M Shayakhmetov, G Stamatoyannopoulos, A Lieber.   

Abstract

Inefficient gene transfer has limited the success of gene therapy in the hematopoietic system. Here we develop a novel chimeric adenovirus (Ad) vector containing Ad serotype 11 fiber-modified capsids and E1/E3 deleted viral genomes (Ad5/11) or genomes devoid of all viral genes (DeltaAd5/11). The capsid-modified vectors transduced human hematopoietic cells more efficiently than the unmodified Ad5-based vector. The absence of viral genes from the DeltaAd5/11 vector allowed for transduction without the associated toxicity seen with the first-generation E1/E3 deleted vector. Chimeric vectors were used for transient expression of the ecotropic retrovirus receptor (ecoR) in Mo7e cells (a CD34-positive, c-Kit-positive, growth-factor-dependent human cell line) as a model for human hematopoietic progenitor cells. Expression of ecoR conferred susceptibility to subsequent retroviral transduction. The DeltaAd5/11 vector used to express ecoR allowed for expansion of retrovirally transduced cells, whereas transduction with the first-generation Ad5/11 vector resulted in cytotoxicity and, over time, loss of cells expressing the retrovirus-vector-derived transgene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472104     DOI: 10.1006/mthe.2000.0410

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  13 in total

1.  Localization of regions in CD46 that interact with adenovirus.

Authors:  Anuj Gaggar; Dmitry M Shayakhmetov; M Kathryn Liszewski; John P Atkinson; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

3.  Development and assessment of human adenovirus type 11 as a gene transfer vector.

Authors:  Daniel Stone; Shaoheng Ni; Zong-Yi Li; Anuj Gaggar; Nelson DiPaolo; Qinghua Feng; Volker Sandig; André Lieber
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.

Authors:  Sebastian Tuve; Hongjie Wang; Carol Ware; Ying Liu; Anuj Gaggar; Kathrin Bernt; Dmitry Shayakhmetov; Zongyi Li; Robert Strauss; Daniel Stone; André Lieber
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

5.  Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection.

Authors:  Hung V Trinh; Guillaume Lesage; Venus Chennamparampil; Benedikt Vollenweider; Christoph J Burckhardt; Stefan Schauer; Menzo Havenga; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

6.  A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.

Authors:  Hongjie Wang; André Lieber
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

7.  A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells.

Authors:  Dmitry M Shayakhmetov; Cheryl A Carlson; Hartmut Stecher; Qiliang Li; George Stamatoyannopoulos; André Lieber
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.

Authors:  Miho Murakami; Hideyo Ugai; Natalya Belousova; Alexander Pereboev; Paul Dent; Paul B Fisher; Maaike Everts; David T Curiel
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

9.  Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber.

Authors:  Takafumi Nakamura; Kenzo Sato; Hirofumi Hamada
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 10.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.